Clinical Trial Update: EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase II single-arm study evaluating Etigilimab (OMP-313M32) with nivolumab in platinum-resistant, recurrent epithelial ovarian cancer; the study is currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• Etigilimab (etigilimab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Ovarian Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING